Silencing of pathogenic B cells offers a potential therapy for SLE
This article has no abstract so we have provided the first paragraph of the full text.
Systemic lupus erythematosus (SLE) is an autoimmune disorder associated with the presence of self-specific antibodies against double-stranded DNA. Current treatments for SLE involve immunosuppressive drugs, which have a range of severe adverse effects. Tchorbanov et al. describe a novel therapy to specifically target the disease-causing B cells.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
